微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2017, Vol. 9 ›› Issue (5): 373-378.doi: 10.3969/j.issn.1674-5671.2017.05.06

• 消化道肿瘤专栏 • 上一篇    下一篇

FPN1、DMT1在肝细胞癌中的表达及其与药物疗效的关系

  

  1. 广西医科大学附属肿瘤医院；广西医科大学研究生院
  • 出版日期:2017-10-25 发布日期:2017-11-02
  • 通讯作者: 李永强 E-mail：lyq702702@126.com
  • 基金资助:

    广西自然科学基金资助项目（2016GXNSFBA380090）；广西科学研究与技术开发计划资助项目（桂科AB16380215）；广西医疗卫生适宜技术开发与推广应用资助项目（S2017101，S201634）

Expression of FPN1 and DMT1 in hepatocellular carcinoma tissues and relationship with efficacy of chemotherapy or sorafenib

  • Online:2017-10-25 Published:2017-11-02

PDF (PC)

404

赞

摘要：

目的 研究膜铁转运蛋白1（ferroportin 1，FPN1）和二价金属离子转运体1（divalent metal transporter 1，DMT1）在人肝细胞癌（hepatocellular carcinoma，HCC）癌组织中的表达及与临床病理特征、药物疗效的关系。方法 回顾性收集行肝癌切除术后复发转移并接受化疗或索拉非尼治疗的HCC患者的临床及病理资料。采用免疫组化法检测HCC癌组织中FPN1及DMT1的表达，分析其与HCC患者临床病理特征、药物疗效的关系。结果 27例HCC患者无完全缓解者，其中接受奥沙利铂联合替吉奥方案化疗16例，获部分缓解2例，疾病稳定2例，疾病控制率（DCR）为25.0%；接受索拉非尼治疗11例，部分缓解1例，疾病稳定 2例，疾病控制率为27.3%。全组患者中位PFS为5.4个月，中位OS为10.0个月。FPN1和DMT1在HCC癌组织中的阳性表达率分别为62.96% 和81.48%，FPN1及DMT1的表达与肿瘤分化程度相关（P＜0.05），与其他临床病理特征无关（P＞0.05）。FPN1阳性患者的DCR为41.2%，中位PFS为6.7个月，中位OS为15.7个月，优于阴性患者的10.0%、1.8个月和8个月（P＜0.05）；DMT1 阳性患者的DCR为18.2%，中位PFS为3.2个月，中位OS为 9.3个月，低于阴性患者的60.0%、18.6个月和35.9个月（P＜0.05）。结论 FPN1和DMT1在HCC中的表达可能受癌细胞分化程度影响，与晚期HCC患者药物治疗后的远期生存有关。

关键词: 肝肿瘤, 膜铁转运蛋白1, 二价金属离子转运蛋白1, 化疗, 靶向药物治疗；索拉非尼

Abstract:

Objective The present study evaluated the expression of Ferroportin 1（FPN1） and  transporter 1（DMT1） in cancer tissues of HCC patients and the potential relationship with clinico-pathological characteristics and efficacy of chemotherapy or sorafenib. Methods Clinical data were retrospectively reviewed for patients who experienced tumor recurrence or metastasis after radical resection and treated by chemotherapy or sorafenib，expression of FPN1 and DMT1 was analyzed in cancer tissues using immunohistochemistry and explored for possible correlation with clinico-pathological characteristics.  Results FPN1 expression was detected in 62.96% of HCC tissues，and DMT1 expression was detected in 81.48%. Expression of each protein correlated significantly with extent of tumor differentiation（P<0.05）. Most patients （16） took chemotherapy consisting of oxaliplatin and S-1，while the remaining 11 took sorafenib. No patients experienced complete remission. Among patients receiving chemotherapy，partial remission occurred in 2 patients and stable disease in 2；altogether，this translated to a disease control rate of 25%. Among patients taking sorafenib，the corresponding numbers were 1，2 and 27.3%. Among all patients，median progression-free survival（PFS） was 5.4 months and median overall survival（OS） was 10.0 months. Among FPN1-positive patients，the disease control rate was 41.2%，median PFS was 6.7 months，and median OS was 15.7 months. The corresponding numbers among FPN1-negative patients were 10.0%，1.8 months and 8 months. Among DMT1-positive patients，the disease control rate was 18.2%，median PFS was 3.2 months，and median OS was 9.3 months. The corresponding numbers among DMT1-negative patients were 60.0%，18.6 months and 35.9 months. Both PFS and OS differed significantly between patients negative or positive for FPN1 or DMT1. Conclusion Expression of FPN1 and DMT1 in HCC cancer tissues is associated with tumor differenti-ation，and may influence HCC patient outcomes，which merits further study.

Key words: Liver neoplasms, Ferroportin 1, Metal transporter 1, Chemotherapy, Targeted therapy, Sorafenib